videos
Video
Quick Chats — Altasciences' One Operational Structure
Chris Perkin, CEO, discusses Altasciences' one operational structure, and how it addresses a major challenge within in the drug development industry.
Video
Quick Chats — Discovering our L.A. Clinical Site: Clinical Study Expertise
Dr. Dave Nguyen, MD, MBA, General Manager and Medical Director, discusses Altasciences' clinical study expertise with ethnobridging, ophthalmology, and vaccine trials. He also shares his insight on what makes Altasciences a different kind of CRO/CDMO.
Video
Quick Chats — The Benefits of a Liquid-Filled Capsule Dosage Form in Clinical Trials
Watch our Executive Vice President of Operations, Ben Reed, explain how scientists can effectively formulate poorly soluble drugs, while reducing development time and costs.
Video
A.T.L.A.S. — Your Roadmap to Drug Development
A custom plan for your unique drug development process, A.T.L.A.S. streamlines your project’s moving parts across all phases, across all of our sites, making it easy and proactive to outsource.
Video
Quick Chats — Partnering with Altasciences for Drug Development and Manufacturing
Altasciences’ expertise combines contract manufacturing and analytical services, including formulation development, Phase I through commercial manufacturing, and ICH stability testing. Watch how we simplify and streamline solutions to offer a full-service, integrated approach to CRO and CDMO services.
Video
Quick Chats — Overcoming Outsourcing Challenges
What are some of the challenges sponsors face when outsourcing early phase drug development? In Part 1 of our Quick Chat, "Shifting the Paradigm", Senior Director of Business Development at Altasciences, Lisa Sanford, answers this question and reveals how Altasciences is shifting the traditional outsourcing paradigm.
Video
Quick Chats — Proactive Drug Development
In Part 2 of our Quick Chat, "Shifting the Paradigm," Lisa Sanford, Senior Director of Business Development at Altasciences, discusses how Altasciences is transforming the traditional outsourcing paradigm to make it easier and faster for sponsors to outsource early phase drug development.